GlassScriptPhysician profile
Tal Mednick
NPI 1700105590
$6,206.47
in general payments reported to CMS, 2019-2025
41 companies · $1,255 in 2025
The $1,255 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.26 · 2020: $286 · 2021: $969 · 2022: $830 · 2023: $1,027 · 2024: $1,756 · 2025: $1,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,018 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,018.41 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,571.31 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $731.15 | 2020-2024 | Ingrezza, Ongentys |
| Pfizer INC. | $435.49 | 2023-2025 | |
| Lundbeck LLC | $337.26 | 2021-2025 | Vyepti, Rexulti |
| Sumitomo Pharma America, INC. | $256.03 | 2023-2024 | Aptiom |
| Amgen INC. | $254.23 | 2020-2024 | Aimovig |
| Argenx US, INC. | $251.27 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Biohaven Pharmaceuticals, INC. | $236.37 | 2020-2021 | |
| Ucb, INC. | $228.67 | 2021-2024 | Briviact, Fintepla |
| Biohaven Pharmaceutical Holding Company LTD. | $212.19 | 2022 | |
| Sk Life Science, INC. | $198.35 | 2021-2025 | |
| Eisai INC. | $148.78 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $141.84 | 2022 | |
| Amneal Pharmaceuticals LLC | $131.93 | 2023-2025 | Rytary, Crexont |
| Emd Serono, INC. | $123.04 | 2019-2024 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tal Mednick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.